Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hepatitis × Ursodeoxycholic Acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 3 Neoplasms 2 Colonic Neoplasms 2 Adenomatous Polyposis Coli 2 Adenoma 2 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Retinoblastoma 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polyps 1 Overweight 1 Obesity 1 Non-alcoholic Fatty Liver Disease 1 Neoplastic Syndromes, Hereditary 1 Neoplasms, Germ Cell and Embryonal 1 Medulloblastoma 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Hepatoblastoma 1 Hepatitis 1 Genetic Diseases, Inborn 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Duodenal Neoplasms 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Chemical and Drug Induced Liver Injury 1 Central Nervous System Neoplasms 1

Interventions

Blood Specimen Collection 2 bavituximab 1 Ursodeoxycholic Acid 1 Surveys and Questionnaires 1 Steroids 1 Spermine Synthase 1 Sorafenib 1 Sofosbuvir 1 Ribavirin 1 Prednisone 1 Phlebotomy 1 Mycophenolic Acid 1 Methylprednisolone Hemisuccinate 1 Methylprednisolone 1 Liquid Biopsy 1 Clinical Protocols 1 Adrenal Cortex Hormones 1 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04810156 2022-12-14

I-HEP

Herlev Hospital

Phase 2 Unknown

Hepatitis, Neoplasms, Chemical and Drug Induced Liver Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡